Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 4/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CLPP | Q16740 | 4/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 8/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 7/20 | 0.32 |
| ▸ | HTR2B | P41595 | 7/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30284329 | 1.00 | TNKS (0.36) | TNKSTNKS2AURKACLPPPARP1 | |
| SCHEMBL23973234 | 0.87 | HTR2C (0.41) | TNKSTNKS2AURKAPARP1HTR2C | |
| SCHEMBL23973230 | 0.85 | HPGD (0.40) | TNKSTNKS2CLPPPARP1HTR2C | |
| SCHEMBL23973233 | 0.85 | TNKS2 (0.39) | TNKSTNKS2PARP1HTR2CMAPT | |
| SCHEMBL23973235 | 0.85 | PARP1 (0.36) | TNKSTNKS2CLPPPARP1HTR2C | |
| SCHEMBL23973229 | 0.84 | TNKS (0.40) | TNKSTNKS2CLPPPARP1HTR2C | |
| SCHEMBL23973137 | 0.83 | MAPT (0.42) | TNKSTNKS2CLPPPARP1HTR2C | |
| SCHEMBL23973236 | 0.82 | TNKS2 (0.39) | TNKSTNKS2CLPPPARP1HTR2C | |
| SCHEMBL23973237 | 0.82 | HTR2C (0.40) | TNKSTNKS2PARP1HTR2CMAPT | |
| SCHEMBL23972481 | 0.82 | HTR2C (0.44) | TNKSTNKS2PARP1HTR2CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142874-B1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | TNKS 1079/4885TNKS2 1601/4885AURKA 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.